Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Paul S. Gaynon, MD

    TitleProfessor of Pediatrics
    SchoolKeck School of Medicine of USC
    DepartmentPediatrics
    AddressCHL Mail Stop 54
    Off Campus
    Los Angeles California 90089
    Phone+1 323 361 2163
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Oberley MJ, Denton C, Ji J, Hiemenz M, Bhojwani D, Ostrow D, Wu S, Gaynon P, Raca G. A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia. Cancer Genet. 2017 Oct; 216-217:91-99. PMID: 29025601.
        View in: PubMed
      2. Gaynon P. Mercaptopurine in childhood acute lymphoblastic leukaemia. Lancet Oncol. 2017 Apr; 18(4):425-426. PMID: 28258829.
        View in: PubMed
      3. Gaynon P. Historical Controls? Haematologica. 2017 Mar; 102(3):e117. PMID: 28250008.
        View in: PubMed
      4. Gaynon P. "The Second Time is Sweeter After All". Br J Haematol. 2017 Feb; 176(4):511-512. PMID: 28145575.
        View in: PubMed
      5. Yeo KK, Gaynon P, Fu CH, Wayne AS, Sun W. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance. J Pediatr Hematol Oncol. 2016 Jul; 38(5):345-9. PMID: 27352191.
        View in: PubMed
      6. Gaynon P, Sun W. Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia. Br J Haematol. 2016 Jun; 173(6):950-7. PMID: 27221005.
        View in: PubMed
      7. Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Aug 15; 22(16):4014-22. PMID: 26920889.
        View in: PubMed
      8. Parekh C, Gaynon P, Abdel-Azim H. Reply: T-Cell Acute Lymphoblastic Leukemia, Minimal Residual Disease, and Lymphocyte Recovery. Pediatr Blood Cancer. 2016 May; 63(5):945. PMID: 26766623.
        View in: PubMed
      9. Matloub Y, Stork L, Asselin B, Hunger SP, Borowitz M, Jones T, Bostrom B, Gastier-Foster JM, Heerema NA, Carroll A, Winick N, Carroll WL, Camitta B, Devidas M, Gaynon P. Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies. Pediatr Blood Cancer. 2016 Feb; 63(2):255-61. PMID: 26485054; PMCID: PMC4715507 [Available on 02/01/17].
      10. Gaynon P. ALL and osteonecrosis. Blood. 2015 Oct 08; 126(15):1734-5. PMID: 26450951.
        View in: PubMed
      11. Meany HJ, Seibel NL, Krailo M, Villaluna D, Chen Z, Gaynon P, Neglia JP, Park JR, Hutchinson R, Sato JK, Wells RJ, Woods WG, Reaman G. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group. J Immunother. 2015 Sep; 38(7):299-305. PMID: 26261894; PMCID: PMC4536569.
      12. Ko RH, Jones TL, Radvinsky D, Robison N, Gaynon P, Panosyan EH, Avramis IA, Avramis VI, Rubin J, Ettinger LJ, Seibel NL, Dhall G. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report. Cancer. 2015 Dec 01; 121(23):4205-11. PMID: 26308766; PMCID: PMC4795901 [Available on 12/01/16].
      13. Meeske KA, Ji L, Freyer DR, Gaynon P, Ruccione K, Butturini A, Avramis VI, Siegel S, Matloub Y, Seibel NL, Sposto R. Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2015 Dec; 62(12):2140-9. PMID: 26173904; PMCID: PMC4624005 [Available on 12/01/16].
      14. Parekh C, Gaynon P, Abdel-Azim H. End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015 Nov; 62(11):2040-3. PMID: 25976383; PMCID: PMC4583337 [Available on 11/01/16].
      15. Sun W, Gaynon P, Sposto R, Wayne AS. Improving access to novel agents for childhood leukemia. Cancer. 2015 Jun 15; 121(12):1927-36. PMID: 25678105; PMCID: PMC4457598.
      16. Hastings C, Gaynon P, Nachman JB, Sather HN, Lu X, Devidas M, Seibel NL. Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (=200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group. Br J Haematol. 2015 Feb; 168(4):533-46. PMID: 25308804; PMCID: PMC4314336.
      17. Liu Y, Tang J, Wakamatsu P, Xue H, Chen J, Gaynon P, Shen S, Sun W. High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemia. Front Pediatr. 2014; 2:96. PMID: 25250304; PMCID: PMC4158872.
      18. Myers DE, Yiv S, Qazi S, Ma H, Cely I, Shahidzadeh A, Arellano M, Finestone E, Gaynon P, Termuhlen A, Cheng J, Uckun FM. CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells. Integr Biol (Camb). 2014 Aug; 6(8):766-80. PMID: 24910947; PMCID: PMC4158964.
      19. Raetz EA, Morrison D, Romanos-Sirakis E, Gaynon P, Sposto R, Bhojwani D, Bostrom BC, Brown P, Eckroth E, Cassar J, Malvar J, Buchbinder A, Carroll WL. A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J Pediatr Hematol Oncol. 2014 Aug; 36(6):458-63. PMID: 24276047; PMCID: PMC4238428.
      20. Orgel E, Sposto R, Malvar J, Seibel NL, Ladas E, Gaynon P, Freyer DR. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group. J Clin Oncol. 2014 May 01; 32(13):1331-7. PMID: 24687836; PMCID: PMC3992723.
      21. Asselin BL, Gaynon P, Whitlock JA. Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion. Curr Opin Oncol. 2013 Dec; 25 Suppl 3:S1-13; quiz S14-6. PMID: 24305505.
        View in: PubMed
      22. Uckun FM, Ma H, Ishkhanian R, Arellano M, Shahidzadeh A, Termuhlen A, Gaynon P, Qazi S. Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients. PLoS One. 2013; 8(11):e80732. PMID: 24278314; PMCID: PMC3835424.
      23. Uckun FM, Qazi S, Cely I, Sahin K, Shahidzadeh A, Ozercan I, Yin Q, Gaynon P, Termuhlen A, Cheng J, Yiv S. Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. Blood. 2013 May 23; 121(21):4348-54. PMID: 23568490; PMCID: PMC3663427.
      24. Acree SC, Tovar JP, Pattengale PK, Wang LL, Church JA, Gaynon P, Cassarino DS. Subcutaneous Panniculitis-like T-cell lymphoma in two pediatric patients: an HIV-positive adolescent and a 4-month-old infant. Fetal Pediatr Pathol. 2013 Jun; 32(3):175-83. PMID: 23092204.
        View in: PubMed
      25. Gaynon P, Harned TM. ABT-751 in relapsed childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2012 Oct; 34(7):583-4. PMID: 22584778.
        View in: PubMed
      26. Mattano LA, Devidas M, Nachman JB, Sather HN, Hunger SP, Steinherz PG, Gaynon P, Seibel NL. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012 Sep; 13(9):906-15. PMID: 22901620; PMCID: PMC3448283.
      27. Messinger YH, Gaynon P, Sposto R, van der Giessen J, Eckroth E, Malvar J, Bostrom BC. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood. 2012 Jul 12; 120(2):285-90. PMID: 22653976.
        View in: PubMed
      28. Lindsay H, Gaynon P. Anaphylactic reaction to etoposide phosphate. Pediatr Blood Cancer. 2012 Oct; 59(4):765. PMID: 22522419.
        View in: PubMed
      29. Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon P, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, Camitta BM, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012 Apr 12; 366(15):1371-81. PMID: 22494120; PMCID: PMC3374496.
      30. Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA, Dillon H, Ratko TA, Wall D, McCarthy PL, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. Biol Blood Marrow Transplant. 2012 Jul; 18(7):979-81. PMID: 22490784.
        View in: PubMed
      31. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon P, Winick NJ, Reaman GH, Carroll WL. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012 May 10; 30(14):1663-9. PMID: 22412151; PMCID: PMC3383113.
      32. Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA, Dillon H, Ratko TA, Wall D, McCarthy PL, Hahn T. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant. 2012 Apr; 18(4):505-22. PMID: 22209888.
        View in: PubMed
      33. Ma H, Qazi S, Ozer Z, Gaynon P, Reaman GH, Uckun FM. CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2012 Jan; 156(1):89-98. PMID: 22017452.
        View in: PubMed
      34. Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, Kadota R, Cooper T, Shen V, Dahl G, Thottassery JV, Jeha S, Maloney K, Paul JA, Barry E, Carroll WL, Gaynon P. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011 Dec 01; 118(23):6043-9. PMID: 21967976; PMCID: PMC3731655.
      35. Gaynon P. A remembrance: James B. Nachman 1948-2011. Pediatr Blood Cancer. 2011 Oct; 57(4):533-4. PMID: 21826779.
        View in: PubMed
      36. Gaynon P. James B. Nachman, 1948 to 2011: a remembrance. J Pediatr Hematol Oncol. 2011 Aug; 33(6):403-5. PMID: 21792033.
        View in: PubMed
      37. Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, La M, Gastier-Foster JM, Heerema NA, Sailer S, Buckley PJ, Thomson B, Cole C, Nachman JB, Reaman G, Winick N, Carroll WL, Devidas M, Gaynon P. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011 Jul 14; 118(2):243-51. PMID: 21562038; PMCID: PMC3138679.
      38. Freyer DR, Devidas M, La M, Carroll WL, Gaynon P, Hunger SP, Seibel NL. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood. 2011 Mar 17; 117(11):3010-5. PMID: 21193696; PMCID: PMC3062307.
      39. Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon P, Loh ML. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer. 2010 Sep; 55(3):421-9. PMID: 20658611.
        View in: PubMed
      40. Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, Sposto R, van der Giessen J, Eckroth E, Bostrom BC. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010 Aug; 55(2):254-9. PMID: 20582937.
        View in: PubMed
      41. Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon P, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer. 2010 Jul 01; 54(7):872-8. PMID: 20127846; PMCID: PMC2857540.
      42. Bonate PL, Cunningham CC, Gaynon P, Jeha S, Kadota R, Lam GN, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer Chemother Pharmacol. 2011 Apr; 67(4):875-90. PMID: 20582417.
        View in: PubMed
      43. Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H, Hutchinson R, Heerema NA, Sorrell AD, Masterson M, Bleyer A, Gaynon P. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood. 2010 Apr 08; 115(14):2740-8. PMID: 20124218; PMCID: PMC2854423.
      44. Gaynon P, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, Hunger SP, Devidas M. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia. 2010 Feb; 24(2):285-97. PMID: 20016531; PMCID: PMC2906139.
      45. Armenian SH, Nash KA, Kapoor N, Franklin JL, Gaynon P, Ross LA, Hoffman JA. Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients. J Pediatr Hematol Oncol. 2009 Dec; 31(12):920-6. PMID: 19855303.
        View in: PubMed
      46. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon P, Loh ML. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010 Feb 01; 28(4):648-54. PMID: 19841326; PMCID: PMC2815999.
      47. Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon P, Hastings C, Mattano LA, Sather H, Devidas M, Freyer DR, Steinherz PG, Seibel NL. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol. 2009 Nov 01; 27(31):5189-94. PMID: 19805689; PMCID: PMC3053149.
      48. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Wang C, Davies SM, Gaynon P, Trigg M, Rutledge R, Burden L, Jorstad D, Carroll A, Heerema NA, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009 Nov 01; 27(31):5175-81. PMID: 19805687; PMCID: PMC2773475.
      49. Sposto R, Gaynon P. An adjustment for patient heterogeneity in the design of two-stage phase II trials. Stat Med. 2009 Sep 10; 28(20):2566-79. PMID: 19521973.
        View in: PubMed
      50. Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R, Luchtman-Jones L, Bomgaars L, Gaynon P, Goldman S, Ritchey K, Arceci R, Altman A, Stine K, Steinherz L, Steinherz P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009 Sep 10; 27(26):4392-7. PMID: 19652076; PMCID: PMC2744276.
      51. Harned TM, Gaynon P. Relapsed acute lymphoblastic leukemia: current status and future opportunities. Curr Oncol Rep. 2008 Nov; 10(6):453-8. PMID: 18928659.
        View in: PubMed
      52. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon P, Carroll WL. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol. 2008 Aug 20; 26(24):3971-8. PMID: 18711187; PMCID: PMC2654313.
      53. Trigg ME, Sather HN, Reaman GH, Tubergen DG, Steinherz PG, Gaynon P, Uckun FM, Hammond GD. Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2008 Jun; 49(6):1142-54. PMID: 18569638.
        View in: PubMed
      54. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 01; 112(5):1646-54. PMID: 18502832; PMCID: PMC2518876.
      55. Harned TM, Gaynon P. Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag. 2008 Apr; 4(2):327-36. PMID: 18728851; PMCID: PMC2504075.
      56. Malempati S, Gaynon P, Sather H, La MK, Stork LC. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J Clin Oncol. 2007 Dec 20; 25(36):5800-7. PMID: 18089878.
        View in: PubMed
      57. Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, Freyer DR, Mattano LA, Hastings CA, Rubin CM, Bertolone K, Franklin JL, Heerema NA, Mitchell TL, Pyesmany AF, La MK, Edens C, Gaynon P. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008 Mar 01; 111(5):2548-55. PMID: 18039957; PMCID: PMC2254538.
      58. Heerema NA, Raimondi SC, Anderson JR, Biegel J, Camitta BM, Cooley LD, Gaynon P, Hirsch B, Magenis RE, McGavran L, Patil S, Pettenati MJ, Pullen J, Rao K, Roulston D, Schneider NR, Shuster JJ, Sanger W, Sutcliffe MJ, van Tuinen P, Watson MS, Carroll AJ. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2007 Jul; 46(7):684-93. PMID: 17431878.
        View in: PubMed
      59. Gaynon P. Treatment of pediatric acute lymphoblastic leukemia: progress achieved and challenges remaining. Curr Hematol Malig Rep. 2007 Jul; 2(3):193-201. PMID: 20425369.
        View in: PubMed
      60. Butturini AM, Dorey FJ, Lange BJ, Henry DW, Gaynon P, Fu C, Franklin J, Siegel SE, Seibel NL, Rogers PC, Sather H, Trigg M, Bleyer WA, Carroll WL. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007 May 20; 25(15):2063-9. PMID: 17513811.
        View in: PubMed
      61. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon P, Camitta BM. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007 Feb 01; 109(3):926-35. PMID: 17003380; PMCID: PMC1785141.
      62. Jarrar M, Gaynon P, Periclou AP, Fu C, Harris RE, Stram D, Altman A, Bostrom B, Breneman J, Steele D, Trigg M, Zipf T, Avramis VI. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer. 2006 Aug; 47(2):141-6. PMID: 16425271.
        View in: PubMed
      63. Gaynon P, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, Steele D, Zipf T, Stram DO, Villaluna D, Trigg ME. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol. 2006 Jul 01; 24(19):3150-6. PMID: 16717292.
        View in: PubMed
      64. Jeha S, Gaynon P, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006 Apr 20; 24(12):1917-23. PMID: 16622268.
        View in: PubMed
      65. Matloub Y, Lindemulder S, Gaynon P, Sather H, La M, Broxson E, Yanofsky R, Hutchinson R, Heerema NA, Nachman J, Blake M, Wells LM, Sorrell AD, Masterson M, Kelleher JF, Stork LC. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood. 2006 Aug 15; 108(4):1165-73. PMID: 16609069; PMCID: PMC1895867.
      66. Gaynon P. Treatment adherence and 6-mercaptopurine metabolites. Pediatr Blood Cancer. 2006 Feb; 46(2):120-1. PMID: 16200555.
        View in: PubMed
      67. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2006 Jan; 12(1):1-30. PMID: 16399566.
        View in: PubMed
      68. Gaynon P. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005 Dec; 131(5):579-87. PMID: 16351633.
        View in: PubMed
      69. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant. 2005 Nov; 11(11):823-61. PMID: 16275588.
        View in: PubMed
      70. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, Heerema NA, Bhatia S. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005 Dec 15; 106(13):4043-9. PMID: 16109782.
        View in: PubMed
      71. Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005 May 20; 23(15):3376-82. PMID: 15908649.
        View in: PubMed
      72. Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon P, Stork LC. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer. 2005 Jan; 44(1):21-8. PMID: 15368546.
        View in: PubMed
      73. Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, Lam GN, Plunkett W, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004 Nov; 44(11):1309-22. PMID: 15496649.
        View in: PubMed
      74. Masera G, Eden T, Schrappe M, Nachman J, Gadner H, Gaynon P, Evans WE, Pui CH. Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004 Aug; 43(2):103-4. PMID: 15236273.
        View in: PubMed
      75. Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon P, Avramis IA, Sather H, Franklin J, Nachman J, Ettinger LJ, La M, Steinherz P, Cohen LJ, Siegel SE, Avramis VI. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004 Apr; 26(4):217-26. PMID: 15087948.
        View in: PubMed
      76. Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon P, Siegel SE, Fingert HJ, Avramis VI. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res. 2004 Mar-Apr; 24(2C):1121-5. PMID: 15154634.
        View in: PubMed
      77. Grigoryan RS, Panosyan EH, Seibel NL, Gaynon P, Avramis IA, Avramis VI. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo. 2004 Mar-Apr; 18(2):107-12. PMID: 15113036.
        View in: PubMed
      78. Reid GS, Terrett L, Alessandri AJ, Grubb S, Stork L, Seibel N, Gaynon P, Schultz KR. Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cells. Leuk Res. 2003 Dec; 27(12):1135-42. PMID: 12921952.
        View in: PubMed
      79. Levy AS, Sather HN, Steinherz PG, Sowers R, La M, Moscow JA, Gaynon P, Uckun FM, Bertino JR, Gorlick R. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study. J Pediatr Hematol Oncol. 2003 Sep; 25(9):688-95. PMID: 12972803.
        View in: PubMed
      80. Wu SQ, Weinberg KI, Joo WJ, Quinn JJ, Franklin J, Siegel SE, Gaynon P. Preponderant mitotic activity of nonleukemic cells plays an important role in failures to detect abnormal clone in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003 Jul; 25(7):520-5. PMID: 12847317.
        View in: PubMed
      81. Hutchinson RJ, Gaynon P, Sather H, Bertolone SJ, Cooper HA, Tannous R, Wells LM, Heerema NA, Sailer S, Trigg ME. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol. 2003 May 01; 21(9):1790-7. PMID: 12721256.
        View in: PubMed
      82. Bostrom BC, Sensel MR, Sather HN, Gaynon P, La MK, Johnston K, Erdmann GR, Gold S, Heerema NA, Hutchinson RJ, Provisor AJ, Trigg ME. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003 May 15; 101(10):3809-17. PMID: 12531809.
        View in: PubMed
      83. Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon P, Robison LL. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood. 2002 Sep 15; 100(6):1957-64. PMID: 12200352.
        View in: PubMed
      84. Gaynon P. Response to Donadieu and Hill "Clinical trials in childhood acute lymphoblastic leukemia: a common prognostic classification and a common induction therapy are now warranted". J Pediatr Hematol Oncol. 2002 Aug-Sep; 24(6):426-8. PMID: 12218587.
        View in: PubMed
      85. Davies SM, Bhatia S, Ross JA, Kiffmeyer WR, Gaynon P, Radloff GA, Robison LL, Perentesis JP. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood. 2002 Jul 01; 100(1):67-71. PMID: 12070010.
        View in: PubMed
      86. Bhatia S, Sather HN, Pabustan OB, Trigg ME, Gaynon P, Robison LL. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002 Jun 15; 99(12):4257-64. PMID: 12036851.
        View in: PubMed
      87. Pui CH, Gaynon P, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer E, Schrappe M, Camitta B. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002 Jun 01; 359(9321):1909-15. PMID: 12057554.
        View in: PubMed
      88. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon P, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS, Stork L. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002 Mar 15; 99(6):1986-94. PMID: 11877270.
        View in: PubMed
      89. Gaynon P. From where do clinical trials come? J Pediatr Hematol Oncol. 2002 Mar-Apr; 24(3):172-4. PMID: 11990301.
        View in: PubMed
      90. Kurre HA, Ettinger AG, Veenstra DL, Gaynon P, Franklin J, Sencer SF, Reaman GH, Lange BJ, Holcenberg JS. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). J Pediatr Hematol Oncol. 2002 Mar-Apr; 24(3):175-81. PMID: 11990302.
        View in: PubMed
      91. Heerema NA, Sather HN, Sensel MG, La MK, Hutchinson RJ, Nachman JB, Reaman GH, Lange BJ, Steinherz PG, Bostrom BC, Gaynon P, Uckun FM. Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia. Cancer. 2002 Feb 15; 94(4):1102-10. PMID: 11920481.
        View in: PubMed